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The onset and progression of skeletal muscle regeneration are controlled by a complex set of interactions between muscle precursor cells
and their environment. Decorin is the main proteoglycan present in the extracellular matrix (ECM) of adult muscle while biglycan expression is
lower, but both are increased in mdx mice dystrophic muscle. Both of these small leucine-rich proteoglycans (SLRPs) can bind other matrix
proteins and to the three TGF-h isoforms, acting as modulators of their biological activity. We evaluated biglycan and decorin expression in
skeletal muscle during barium chloride-induced skeletal muscle regeneration in mice. A transient and dramatic up-regulation of biglycan was
associated with newly formed myotubes, whereas decorin presented only minor variations. Studies both in vitro and in intact developing
newborn mice showed that biglycan expression is initially high and then decreases during skeletal muscle differentiation and maturation. To
further evaluate the role of biglycan during the regenerative process, skeletal muscle regeneration was studied in biglycan-null mice. Skeletal
muscle maintains its regenerative capacity in the absence of biglycan, but a delay in regenerated fiber growth and a decreased expression of
embryonic myosin were observed despite to normal expression of MyoD and myogenin. Transient up-regulation of decorin during muscle
regeneration in these mice may possibly obscure further roles of SLRPs in this process.
D 2004 Elsevier Inc. All rights reserved.Keywords: Biglycan; Decorin; Embryonic myosin; Proteoglycans; Skeletal muscle regeneration
Introduction After skeletal muscle injury, released signals induce theirIn mammals, skeletal muscle formation continues post-
natally during growth of muscle masses and as a damage-
induced regenerative response. Muscle regeneration main-
tains muscle function in aging and delays functional
impairment caused by progressive neuromuscular diseases
such as Duchenne muscular dystrophy. Satellite cells,
mononucleated cells located at the periphery of mature
myofibers and beneath its basal lamina, constitute the main
source of muscle precursor cells for growth and repair.0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2003.12.025
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E-mail address: ebrandan@genes.bio.puc.cl (E. Brandan).reentry into the cell cycle and their migration into the
damaged zone where they proliferate and differentiate into
mature myofibers.
Differentiation of muscle precursor cells is regulated by
the expression of specific combinations of muscle regulatory
transcriptions factors, especially from a family of basic helix-
loop-helix transcription factors denominated muscle regula-
tory factors (MRFs). Among the MRFs, myf-5 and MyoD
are expressed first by activated satellite cells, associated with
proliferation of determined muscle precursors, and are then
followed by the expression of myogenin, which triggers
terminal differentiation, and by MRF-4, which is expressed
in differentiated muscle (Cornelison and Wold, 1997; Seale
and Rudnicki, 2000). Myogenin expression, in cooperation
with other transcription factors such as myocyte enhancer
factor 2 (MEF-2), leads to muscle precursor cell fusion and
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kinase or myosin heavy chains, which follow a transition
from developmental to adult isoforms.
Growth factors such as transforming growth factor-h
(TGF-h), insulin-like growth factors (IGF), hepatocyte
growth factor (HGF), and members of the fibroblast growth
factor (FGF) family are among the known extracellular
signals that control skeletal muscle differentiation. A satel-
lite cell line derived from regenerating adult mouse skeletal
muscle, C2C12, undergoes in vitro terminal myogenic
differentiation after serum removal from the culture medi-
um (Blau et al., 1985; Yaffe and Saxel, 1977). The
surrounding extracellular matrix (ECM) is also likely to
play an important role in growth control and differentiation.
It acts not only as a scaffold for the cells but as a reservoir
of growth factors and cytokines, regulating their activation
status and turnover. Also, several ECM molecules exhibit
direct signaling functions (Boudreau and Bissell, 1998;
Kresse and Schonherr, 2001; Lukashev and Werb, 1998).
In the C2C12 cells, disorganization of the ECM, caused by
the inhibition of proteoglycan sulfation, affects the proper
progression of the myogenic program independently of
myogenin expression (Melo et al., 1996; Osses and Bran-
dan, 2001). In vivo, muscle injuries that destroy the muscle
basal lamina generally present a poorer functional recovery
than injuries that minimally disrupt its integrity and orien-
tation (Sanes, 2003).
Decorin and biglycan are two chondroitin sulfate or
dermatan sulfate (CS/DS) ECM proteoglycans of the SLRP
family, which bind to TGF-hs, collagens, and other matrix
proteins (for a review, see Ameye and Young, 2002; Iozzo,
1998). In adult skeletal muscle tissue, decorin is the most
abundant proteoglycan and is found mainly in the perimy-
sium (Brandan et al., 1992). The synthesis and expression of
decorin are up-regulated during skeletal muscle differentia-
tion in vitro (Brandan et al., 1991). However, decorin
expression in myoblasts is required for preventing terminal
differentiation: antisense inhibition of its expression in
C2C12 myoblasts accelerates skeletal muscle differentiation
by decreasing sensitivity to TGF-h signaling (Riquelme et
al., 2001). Biglycan, on the other hand, is expressed by
secondary myotubes during fetal muscle formation (Bianco
et al., 1990) and, in the adult, is localized preferentially in the
endomysium and in certain NMJs, probably complexed to
the dystrophin-associated protein complex through its bind-
ing to a-dystroglycan (Bowe et al., 2000). Both decorin and
biglycan are up-regulated in the ECM of the dystrophic
muscle of the mdx mouse (Bowe et al., 2000; Caceres et al.,
2000; Porter et al., 2002). This mouse model of Duchenne
muscular dystrophy presents a much milder phenotype than
human patients because of the functional compensation of
dystrophin by utrophin (Grady et al., 1997) and enhanced
muscle regeneration (Pagel and Partridge, 1999). Decorin
and biglycan are also increased in the skeletal muscle of
Duchenne muscular dystrophy patients, as has been de-
scribed with microarray analyses (Haslett et al., 2002), butthis increase appears to be mostly associated with fibrotic
tissue (Alvarez et al., unpublished results).
In this study, decorin and biglycan expressions were
evaluated in a mouse model of skeletal muscle regeneration.
Interestingly, their expression during muscle regeneration
was differentially regulated. A dramatic and transient in-
crease in biglycan expression associated with regenerating
myotubes was observed, whereas decorin remained relative-
ly unchanged. Biglycan expression was studied during
animal muscle growth and in vitro myogenesis, and its role
in skeletal muscle regeneration was assessed by studies in
biglycan-null mice.Materials and methods
Animals
C57BL/6 wild-type male mice of 2–12 weeks of age
and biglycan-deficient mice of 8–12 weeks of age were
studied. These mice were generated by gene targeting by
homologous recombination as described previously (Chen
et al., 2002; Xu et al., 1998). Biglycan gene, Bgn, is
located on chromosome X so wild-type male mice have a
genotype of Bgn+/0 and the mutant male mice, which do
not express either biglycan mRNA or its protein, are Bgn/
0. The animals were kept at room temperature with a 24-
h night–day cycle and fed with pellets and water ad
libitum. All protocols were conducted under strict accor-
dance and with the formal approval of Brown University’s
Institutional Animal Care and Use Committee and the
Animal Ethics Committee of the P. Universidad Cato´lica
de Chile.
Experimental muscle injury
Injury of normal muscles in animals of 8–12 weeks of
age was performed by barium chloride injection (Caldwell
et al., 1990) in mice under ketamine/xylazine anesthesia
(80:12 mg/kg bw ip). Briefly, 60 Al of 1.2% m/v BaCl2
aqueous solution was injected along the whole length of
the left Tibialis anterior muscle (TA). Contralateral non-
injected muscles were used as controls. After different
recovery times (range 2–15 days), TA were dissected and
removed under anesthesia and the animals were sacrificed.
Tissues were rapidly frozen and stored at 80jC until
processing.
Cell culture
The mouse skeletal muscle cell line C2C12 (ATCC, VA),
derived from adult mouse leg muscle, was grown and
induced to differentiate as described previously (Larrain et
al., 1997, 1998). Differentiating cells were synchronized by
the addition of AraC, an inhibitor of cell proliferation, to the
differentiation medium since the second day.
ntal BRNA isolation and Northern blot analysis
Total RNA was isolated from skeletal muscles as
described (Brandan et al., 1992; Chomczynski and Sacchi,
1987). Eight to 10 Ag RNA samples were electrophoresed
in 1.2% agarose/formaldehyde gels, transferred to Nytran
membranes (Schleicher and Shuell, Dassel, Germany), and
hybridized with random primed [32P]-dCTP-labeled cDNA
probes for biglycan, decorin, MyoD, and myogenin in
hybridization buffer at 65jC as described previously
(Brandan et al., 1992; Brandan et al., 1996; Riquelme
et al., 2001). The biglycan probe, 625 nt long, was
amplified by PCR from mouse liver cDNA as described
below. Hybridized membranes were washed twice at
65jC and exposed to Kodak X-ray film. To normalize
signal intensity, blots were later stripped and rehybridized
with a GAPDH or an 18S 32P-labeled probes kindly
donated by Dr. J. Chianale (Department of Gastroenter-
ology, Faculty of Medicine, P. Universidad Cato´lica de
Chile, Chile).
RT-PCR analyses
Two micrograms of total RNA from each sample were
used for cDNA generation with a recombinant M-MLV
reverse transcriptase (Invitrogen, CA) and random hexamers
as primers. The cDNAs were amplified using the following
primers: biglycan, 5V-TCCCCAGGAACATTGACCAT-3V
and 5V-GTTCAAAGCCACTGTTCTCCA-3V; embryonic
myosin heavy chain, 5V-GGAGACACGGATCAGA-
GAGC-3V and 5V-CAGCCTGCCTCTTGTAGGAC-3V;
and 18S RNA, 5V-TAGAGCTAATACATGCCGACG-3V
and 5V-TTAATCATGGCCTCAGTTCCG-3V. Samples were
denatured at 94jC for 5 min, followed by amplification
rounds consisting of denaturing at 94jC for 30 s, annealing
at 60jC or 57jC (biglycan) for 90 s and extension at 72jC
for 90 s through 32 cycles in the case of biglycan and
embryonic myosin, and 24 for 18S RNA; thus, all reactions
were performed within the linear range of amplification for
each pair of primers. Final extension at 72jC for 10 min was
allowed. The products were size-fractionated by electropho-
resis through 1.5% agarose gels and stained with ethidium
bromide. Images of the gels were acquired with Gel Doc
system and analyzed with the software Quantity OneR (Bio-
Rad Laboratories, CA).
Labeling of skeletal muscle proteoglycans
Four or 6 days after the induction of muscle injury, a
group of mice was injected intraperitoneally with 3 mCi
sodium [35S]-sulfate (New England Nuclear, MA) in 0.15 M
NaCl each, divided into four individual injections separated
by 3 h (Brandan and Inestrosa, 1987). Twenty four hours
later, the animals were sacrificed and TA muscles were
excised and subjected to protein extraction protocols as
described below.
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Protein extracts were prepared with a protocol slightly
modified from the one previously described by Brandan and
Inestrosa in 1987. Briefly, skeletal muscle was homogenized
in 4 M guanidine–HCl, 0.05 M sodium acetate (pH 5.8),
and 1 mM PMSF at 4jC and maintained under agitation for
18 h. The supernatant was equilibrated by dialysis with 8 M
urea, 0.2 M NaCl, 0.05 M sodium acetate, and 0.5% Triton
X-100 to remove guanidine. Samples were concentrated by
DEAE-Sephacel anion-exchange chromatography, equili-
brated and washed with the same urea buffer, and eluted
with 1.0 M NaCl. The extracts were finally equilibrated by
dialysis with a buffer containing 100 mM Tris–HCl, 50 mM
NaCl, pH 7.5, previous to enzymatic treatments. For alka-
line extraction of biglycan (modified from Bowe et al.,
2000), the tissue was homogenized in 50 mM Tris, pH 12.0,
containing protease inhibitors (10 Ag/ml leupeptin, 100 Ag/
ml benzamidine, 50 Ag/ml aprotinin, 100 Ag/ml trypsin
inhibitor, and 1 mM PMSF) at 4jC, maintained under
agitation for 1 h at room temperature, and centrifuged 30
min at 20,000  g and 4jC. The supernatants were
neutralized with 10 mM Tris–HCl, pH 6.0 to a pH between
7 and 8, and then concentrated by DEAE-Sephacel anion-
exchange chromatography, as described above. Protein
content was determined as described previously (Riquelme
et al., 2001).
Enzymatic digestions
Chondroitinase ABC (Sigma, MO) and heparitinase (Sei-
kagaku Corporation, Tokio, Japan) digestion of proteogly-
cans were performed as previously described (Brandan and
Inestrosa, 1987; Brandan et al., 1992).
Determination of proteoglycan-associated radioactivity
Aliquots of the digested material from the extracts of
metabolically labeled muscle were spotted on dry Whatman
3 MM filter discs impregnated by prior soaking in 2.5%
cetylpyridinium chloride (CPC; Caceres et al., 2000). The
filter discs were washed sequentially in 25 mM sodium
sulfate, distilled water, and 95% ethanol and then dried for
scintillation counting. A 2-h incubation with 20% trichloro-
acetic acid was performed in between washes with distilled
water. GAG-containing material binds quantitatively to these
discs, but disaccharides generated by the digestion or cleav-
ages do not (Rapraeger and Bernfield, 1985).
SDS-PAGE analysis of proteoglycans
Appropriate samples were digested with chondroitinase
ABC or heparitinase and then analyzed by SDS-PAGE
followed by fluorography using a 4–15% acrylamide gradi-
ent in the separation gel as previously described (Caceres et
al., 2000).
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Fig. 1. Proteoglycan synthesis is increased in skeletal muscle regeneration.
(A) After metabolic labeling with [35S]-sulfate, radioactivity associated with
proteoglycans in samples from control muscle and 5 days after barium
chloride injection was determined by binding to CPC-impregnated filters as
described in Materials and methods. In regenerating muscle, a greater than
ten-fold increase in sulfate incorporation into proteoglycans was observed,
maintaining a proportion of about 80% CS/DS proteoglycans. (B) SDS-
PAGE fractionation in 4–15% gradient gels of the labeled muscle samples
and fluorography shows that the observed increase in proteoglycan content is
mainly associated to CS/DS species of 100–130 and 200–300 kDa and a
band of CS/DS and HS proteoglycans of higher apparent molecular mass.
Migration of molecular mass standards is shown on the left (C ABC,
chondroitinase ABC; Hase, heparitinase).
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For proteoglycan detection, appropriate samples contain-
ing equivalent amounts of proteins were incubated with
chondroitinase ABC and then analyzed by SDS-PAGE
using a 4–15% acrylamide gradient in the separation gel.
Proteins were electrophoretically transferred to nitrocellu-
lose membranes, detected with anti-D-mouse biglycan LF-
106 or anti-mouse decorin LF-113 polyclonal antibodies
(both were kindly donated by Dr. L. Fisher, NIDR, NIH,
Bethesda, MD; Fisher et al., 1995) and visualized by
enhanced chemiluminescence (Pierce, IL). Corresponding
samples from the total homogenate in urea buffer were also
analyzed by immunoblot as described above, with mono-
clonal antibodies against myogenin (Olguin and Brandan,
2001) and embryonic myosin F1.652 [developed by Dr H.
Blau (Silberstein et al., 1986) and obtained from the
Developmental Studies Hybridoma Bank, developed under
the auspices of the NICHD and maintained by The Univer-
sity of Iowa, Department of Biological Sciences, Iowa City,
IA].
Histology and immunohistochemistry
Cryostat sections (6 Am) of control and treated TA at
different times after BaCl2 injection were fixed for 20 min in
3% paraformaldehyde in phosphate-buffered saline (PBS),
pH 7.4, and stained with hematoxilin–eosin (H.E.) or
blocked with 8% BSA in PBS and treated with 2.5 mU
chondroitinase ABC for 2 h at 37jC (Bianco et al., 1990)
previous to an overnight incubation at 4jC with primary
antibodies against biglycan LF-51 (in 1:300 dilution),
decorin LF-113 (in 1:700 dilution), and embryonic myosin
F1.652 (1:100). Sections were then washed and incubated
with either anti-rabbit FITC or anti-mouse TRITC (all
diluted 1:100, Pierce) for 1 h at room temperature. For
nuclear staining, sections were incubated with 1 Ag/ml
Hoechst 33258 in PBS for 10 min. After rinsing, the
sections were mounted with fluorescent mounting medium
(Dako Corporation, CA) under glass cover slips and viewed
and photographed with a Nikon Eclipse microscope
equipped for epifluorescence. Specificity of anti-biglycan
and anti-decorin antibodies was assayed by the observation
of absence of staining after preincubation with an over
tenfold excess of the purified proteoglycans subjected to
chondroitinase ABC digestion.
For the assessment of fiber diameters, images from H.E.-
stained cross sections from Bgn+/0 and Bgn/0 muscles
were obtained with the Nikon ACT-1 version 2.12 software
and a Nikon DXM1200 CCD digital camera. For each
muscle (n = 2–3 for each different time point), two 10
field images were selected from the zones that presented the
greatest variability in the diameters of the fiber. The lesser
diameter of each fiber in the field (over 1000 for each
muscle) was measured with the Adobe PhotoShop 5.0
software.
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Increased synthesis of CS/DS proteoglycans during skeletal
muscle regeneration
Injection of a 1.2% barium chloride solution induces
necrosis of skeletal muscle fibers followed by the regenera-
tion of the tissue (Caldwell et al., 1990; Casar et al., 2004).
Briefly, as we have previously described (Casar et al., 2004),
an enlargement of the intercellular space separating necrotic
fibers, together with the appearance of abundant mononucle-
ated cells, is observed the first 3 days after the injection.
These cells are mainly inflammatory cells—predominantly
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dle-shaped activated and proliferating satellite cells. Regen-
erated myotubes, with the nuclei in central position, appear
by day 4 or 5. By the seventh day, most fibers in a cross
section of different zones of an injected TA present central
nuclei, but their diameters are still highly heterogeneous. By
the 15th day after the injection, the tissue has recovered most
of its normal morphology, but regenerated fibers present
central nuclei and a slight increase in the interstitial space is
still observed.
As a global approach to proteoglycan synthesis during
skeletal muscle regeneration, intraperitoneal injection of
[35S]-sulfate was performed the fourth day after barium
chloride injection, that is, a time when massive muscle
differentiation has started, but some degree of muscle pre-
cursors proliferation can still be found. After 24 h of meta-
bolic labeling, both the injured and the contralateral spared
muscle were harvested and protein extracts were prepared
and enriched in proteoglycans by anion-exchange chroma-
tography. Proteoglycan content in these extracts was evalu-
ated by binding to CPC impregnated filters. In control
muscle, as has been previously described (Andrade andFig. 2. Biglycan expression is transiently increased during skeletal muscle regen
increase from the second day after the barium chloride injection until around the
induction of myogenin expression. Decorin transcript levels, in contrast, do n
regeneration as compared to basal levels. Hybridization with a probe for 18S ribo
increases transiently during skeletal muscle regeneration as is detected on the fifth
ABC-treated extracts. Decorin core protein levels only show minor variations an
metabolic labeling of proteoglycans with [35S]-sulfate 6 days after barium chlor
species with an electrophoretic migration pattern previously described for biglyca
showed on the right (CABC, chondroitinase ABC).Brandan, 1991; Brandan et al., 1991), most of the label
was associated to CS/DS proteoglycans and the remaining
was sensitive to heparitinase digestion. In regenerating
muscle, a remarkable—about tenfold—increase in proteo-
glycan-associated sulfate labeling was observed, being still
around 80% of the radioactivity sensitive to chondroitinase
ABC digestion. Aliquots from these extracts, equivalent in
protein content, were fractionated by SDS-PAGE and sub-
jected to fluorography for a further approach to the identity
of the different proteoglycan species involved (Fig. 1). The
main species in normal muscle is decorin, a CS/DS proteo-
glycan that migrates around 70–90 kDa (Brandan et al.,
1992), which appears together with a less intense band of
high molecular weight heparan sulfate proteoglycans (i.e.,
sensitive to heparitinase digestion, data not shown). In
regenerating skeletal muscle, in contrast, two CS/DS species
appear, which migrate as broad heterogeneous bands around
120 and 250 kDa, respectively, and likely correspond to the
forms of biglycan substituted with one or two glycosamino-
glycan chains (Fisher et al., 1989). An increase in the label of
higher relative molecular mass species is also observed in
regenerating muscle, mostly associated with an increase ineration. (A) In Northern blot studies, biglycan steady state mRNA levels
seventh day, parallel to the early stages of myogenesis as indicated by the
ot show major variations and only a slight increase is observed during
somal RNA is presented as a gel-loading control. (B) Biglycan core protein
and seventh day after the injection in Western blot studies of chondroitinase
d is high at all time points. (C) SDS-PAGE of samples of TA subjected to
ide injection and alkaline solubilization shows an increase of two CS/DS
n (Fisher et al., 1989). Coomassie blue staining of the proteins in the gel is
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(Casar et al., 2004). However, this high molecular weight
smear appears to be partially sensitive to chondroitinase
ABC digestion, probably reflecting an increase in other
CS/DS proteoglycans of high molecular weight such as
versican or complex formation by smaller proteoglycans
such as decorin and biglycan. Together, these results show
that quantitative and qualitative changes in small CS/DS
proteoglycans occur in skeletal muscle during regeneration.
Transient increase of biglycan expression during skeletal
muscle regeneration
Characterization of CS/DS SLRP expression during bar-
ium-chloride-induced skeletal muscle regeneration in TA
muscle was performed. The expression of biglycan and deco-
rin transcripts was studied in mouse TA skeletal muscle
during regeneration by Northern blot (Fig. 2A). In adult
skeletal muscle, biglycanmRNA expression is comparatively
low, being almost undetectable in the conditions studied.
During regeneration, a transient and dramatic increase inFig. 3. Biglycan increase is localized in nascent new myotubes in regenerating skel
(A and D) and regenerating TA at five (B, E, G, H, and I) and 15 days (C and F)
observed in areas of newly formed myotubes on the fifth day after barium chloride
In control muscle, biglycan is localized preferentially in the endomysium, whereas
at the endomysium, but mostly at the perimysium. During regeneration, decorin is
connective tissue. By the 15th day after barium chloride injection, distribution of
regenerating myotubes basement membranes are indicated by an arrowhead; the pe
In G–I, higher magnification microphotographs show that during regeneration, bi
positive staining for embryonic myosin in adjacent tissue sections (detected wi
(arrows). Specificity of the staining was confirmed by absorbing anti-biglycan a
biglycan (I). The scale bar indicates 50 Am.biglycan mRNA expression is observed; it starts around the
second day after barium chloride injection, peaks between the
third and fourth day after the injection, and then decreases to
reach the basal level towards the seventh day. This time
course is coincident with the early differentiation of regen-
erated myotubes, as reflected by up-regulation of the tran-
scripts of the MRF myogenin. Decorin mRNA, in contrast,
appears to show small variations during the process, present-
ing only a slight increase that is observed on the first days
after the injection.
Western blots were performed to study if differences in
mRNA levels were reflected in changes of the core protein
levels of these proteoglycans (Fig. 2B). After fractionation
and blotting of chondroitinase ABC-treated samples, anti-
biglycan polyclonal antiserum LF-106 recognizes a protein
that migrates as a globular protein of 48 kDa and whose
content is transiently increased on days 5 and 7 after BaCl2
injection. Anti-decorin antibodies recognize a protein that
migrates with a slightly smaller relative molecular mass, de-
tectable in control muscle and whose content persists without
major variations during regeneration. As LF-106 antibodiesetal muscle. Indirect immunofluorescence studies in cross sections of control
after barium chloride injection. An increased biglycan immunodetection is
injection (as detected with an FITC-conjugated second antibody, A–C, G).
decorin (detected with TRITC-conjugated antibodies, D–F) is localized also
detected at the periphery of myotubes and myofibers and in the interstitial
both proteoglycans resembles that of control muscle. The endomysium and
rimisium and interstitial tissue during regeneration are indicated by an arrow.
glycan increase is associated to newly formed myotubes (G), which show a
th TRITC-conjugated antibodies, H), and is absent from interstitial cells
ntibodies with an excess of chondroitinase ABC-digested purified mouse
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metabolically labeled with [35S]-sulfate on the sixth day after
barium chloride injection and both TA muscles were har-
vested 24 h later and subjected to alkaline solubilization to
partially isolate biglycan (modified from Bowe et al., 2000).
SDS-PAGE and fluorography of these extracts show a signi-
ficant increase during regeneration of two CS/DS species that
migrate as broad bands around 250 and 120 kDa, respectively
(Fig. 2C). Taken together, these results show that during
skeletal muscle regeneration in the TA, biglycan is the main
CS/DS proteoglycan presenting an important transient in-
crease in its expression, at both mRNA and proteoglycan
levels.
The tissue localization of up-regulated biglycan was
studied by indirect immunofluorescence (Fig. 3). Biglycan
immunoreactivity in normal adult skeletal muscle is local-
ized in the endomysium, with a relatively high backgroundFig. 4. Biglycan expression decreases with skeletal muscle differentiation and matu
skeletal muscle is high in 2-week-old mice, when muscle formation is still underw
then decreases progressively with age until adulthood. (B) In the skeletal muscle ce
regulated with muscle differentiation. (C) Decorin expression, on the contrary, is lo
(15 Ag) were analyzed with [32P]-labeled probes. Hybridization with a GAPDH prob
skeletal muscle differentiation in the conditioned media of C2C12 cells. Western bl
cells at different days after the induction of differentiation, concentrated by DEAEfrom the muscle fiber’s cytoplasm (Fig. 3A). During regen-
eration, its immunoreactivity persists selectively localized
around skeletal muscle fibers, with greater intensity around
newly formed myotubes at the fourth (not shown) and fifth
day after the injection (Figs. 3B and G). These new
myotubes are characterized by their small diameter, pres-
ence of central nuclei, and expression of embryonic isoform
of myosin in their cytoplasm (Fig. 3H). Interestingly,
biglycan staining is absent from interstitial mononuclear
cells (arrows, Fig. 3G). By the 15th day after BaCl2
injection, biglycan staining is similar to that observed in
control muscle (Fig. 3C). Decorin immunoreactivity, on the
other hand, is localized preferentially at the perimysium and
also at the endomysium of normal muscle tissue (Fig. 3D).
This localization is not changed after the injury when
decorin is detected both surrounding the nascent myotubes
and persistent fibers and in the enlarged strips of connectiveration, both in vitro and in vivo. (A) Biglycan mRNA expression in hindlimb
ay as is apparent by the maintained expression of myogenin transcripts, and
ll line C2C12, biglycan mRNA expression is high in myoblasts and is down
w in myoblasts and high in myotubes. Northern blots of total RNA samples
e was used as a gel-loading control. (D) Biglycan core protein decreases with
ot of chondroitinase ABC treated samples of conditioned media from C2C12
chromatography. Molecular mass standards are shown on the right.
J.C. Casar et al. / Developmental Biology 268 (2004) 358–371 365tissue where most mononuclear cells are localized (Fig. 3E).
As is the case for biglycan, by day 15, decorin distribution is
similar to that observed in normal muscle, although with a
small increase of the signal around muscle fibers, as a slight
enlargement of the endomysial space is still observed (Fig.
3F). These histological results show that the observed up-
regulation of biglycan is associated with regenerating myo-
tubes and suggest that its transient increase may relate to the
initial phases of muscle formation.
Biglycan expression decreases with maturation and
differentiation of skeletal muscle
In view of the low levels of biglycan in adult skeletal
muscle and its transient increase during regeneration, weFig. 5. Morphological progression and MRF expression during skeletal muscle reg
muscle regeneration after barium chloride injection is similar in wild-type (Bgn+/0)
bar indicates 50 Am. (B) The temporal pattern of expression of the transcripts fo
compared to wild-type mice is shown. Northern blots of samples of total RNA (8 A
with [32P]-labeled probes. Hybridization with a probe for 18S ribosomal RNA w
muscle regeneration in wild-type and biglycan-null mice was also studied by Weste
in Bgn/0 muscle, although a slight delay in the onset of myogenin expression inext determined the time course of biglycan mRNA during
normal postnatal development and maturation of mouse
hind limb skeletal muscle by Northern blot (Fig. 4A).
During the first weeks after birth, muscle formation con-
tinues as required by the animal growth (Buckingham,
1992). Interestingly, biglycan mRNA expression is higher
at the youngest age studied (2 weeks), coincident with on-
going muscle formation as reflected by detectable myoge-
nin mRNA expression. Biglycan mRNA expression then
gradually decreases to the low levels characteristic of the
adult.
Changes in the expression of biglycan during myogenic
differentiation in vitro were studied in C2C12 cells. Bigly-
can transcripts are highly expressed by proliferating C2C12
cells. After the induction of differentiation, it progressivelyeneration of biglycan-null mice. (A) The morphological progress of skeletal
and biglycan-null mice (Bgn/0). H.E. staining of cross sections. The scale
r the MRFS MyoD and myogenin in regenerating muscle from Bgn/0 as
g) from TA muscle at different days after barium chloride injection, analyzed
as used as a gel-loading control. (C) Myogenin expression during skeletal
rn blot. No difference is observed in the overall time course of its expression
s apparent. A standard of molecular mass is shown on the right.
J.C. Casar et al. / Developmental B366decays until the sixth day, when abundant myotubes are
present in the culture (Fig. 4B). Myogenin mRNA is
detectable only after differentiation is induced, and at the
fourth day it starts to decrease. As in the in vivo studies,
biglycan’s core protein presented a similar pattern to its
mRNA expression and was down-regulated with myogene-
sis of C2C12 cells (Fig. 4D). The expression pattern
observed for biglycan in these cells is opposite to the pattern
observed for decorin (Brandan et al., 1991), which has a low
expression by myoblasts and increases with differentiation
(Fig. 4C).
Taken together, the in vivo and in vitro results
suggest that biglycan is expressed by activated or pro-
liferating muscle precursor cells and during the first steps
of myogenesis and is then down-regulated with low
levels persisting around the periphery of mature fibers
in vivo.Fig. 6. Skeletal muscle regeneration in Bgn/0 mice shows slower growth of th
The distribution of muscle fiber diameters is presented for the wild type (Bgn+
from control muscle and muscles after 7 and 12 days from barium chloride i
points studied). No difference in the fiber diameter distribution was observed
was significantly different 7 days after the injection of barium chloride into mu
Mann–Whitney rank sum test). (B) Embryonic myosin expression during ske
Bgn+/0 and Bgn/0 muscle from different days after barium chloride injecti
muscle during regeneration, although levels of total muscle myosin were comp
shown on the left. (C) Semiquantitative RT-PCR was performed to study embr
muscle regeneration. Amplification of 18S cDNA was used as a loading contro
biglycan-null muscle, the increase in EMHC expression is lower and is delaye
n = 3).Delayed fiber growth and diminished expression of myosin
isoforms during skeletal muscle regeneration in
biglycan-null mice
The transient up-regulation of biglycan during skeletal
muscle regeneration suggests a function for this SLRP in
adult myogenesis. To test this hypothesis, we studied
regeneration in mice with targeted inactivation of biglycan
by homologous recombination. Biglycan-null mice show
abnormalities in collagen fibril formation and a late onset
(>6 months) osteoporotic phenotype characterized by im-
paired bone formation, osteoarthritis, and ectopic tendon
ossification (Ameye et al., 2002; Corsi et al., 2002; Xu et
al., 1998). These mice also present a mild myopathy, with
instability of the sarcolemma and scattered foci of necrotic
and regenerating myofibers (Rafii et al., 2000). Skeletal
muscle regeneration was induced in 8-week-old mice by
iology 268 (2004) 358–371e regenerated fibers and decreased expression of embryonic myosin. (A)
/0), and biglycan-null (Bgn/0) mice are presented for midbelly sections
njection (n = 2–3 muscles in each group for each of the different time
in basal conditions in Bgn+/0 and Bgn/0 muscle, but the distribution
scle and the difference was even more notorious by day 12 (*P < 0.001,
letal muscle regeneration was studied by Western blot in extracts from
on. A decreased content of this isoform was detected in biglycan-null
arable to the observed in wild-type mice. Molecular mass standards are
yonic myosin heavy chain (EMHC) transcripts expression during skeletal
l. Densitometric quantification of the products graphically shows that in
d as compared to wild-type animals (lower panel, n = 3; average F SD,
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difference in the morphological progression of skeletal
muscle regeneration was observed in Bgn/0 as compared
to wild-type mice. Three days after the injection, extensive
degeneration of myofibers and abundant mononuclear cells
were observed; by the fifth day, numerous newly formed
myotubes were apparent; and from days 7 to 12, tissue
morphology was grossly restored by centrally nucleated
myofibers (Fig. 5A). The expression of mRNA of the MRFs
MyoD and myogenin, early markers and regulators of the
myogenic process, was studied by Northern blot (Fig. 5B).
No differences in their temporal pattern of expression were
observed between wild-type and Bgn/0 mice. The tempo-
ral pattern of myogenin protein expression was also similar
in both groups in Western blot studies, although a slight
delay in the onset of its expression was apparent in Bgn/0
mice (Fig. 5C).
When muscle fiber diameters were assessed, a difference
was observed in skeletal muscle fiber growth during regen-
eration (Fig. 6A). No difference was found in the basal fiber
diameter distribution in the TA of any of the groups of mice,
indicating that skeletal muscle formation and myofiberFig. 7. Decorin is increased in Bgn/0 mice during skeletal muscle regeneration.
extracts from regenerating muscle of wild-type (Bgn+/0) and biglycan-null (Bgn/0
observed on the seventh day after barium chloride injection. In the absence of bigl
day. Molecular mass standards are shown on the right. (B) By indirect immunofluo
skeletal muscle is observed on the fifth and seventh days after barium chloride inje
Some degree of faint unspecific binding is detected in Bgn/0 sections. The endom
arrowhead; the perimisium and interstitial tissue during regeneration are indicatedgrowth in this skeletal muscle are not affected by long-term
in the absence of biglycan. However, at the seventh day after
barium chloride injection, the frequency distribution of the
diameters of the regenerated fibers was significantly differ-
ent in Bgn/0 compared to wild-type muscle (P < 0.001,
Mann–Whitney rank sum U test), where the myotubes in
null-mice muscle were slightly thinner, even though their
modal diameter was similar. This difference became more
evident at the 12th day after the injection where Bgn/0
muscle showed a smaller modal fiber diameter, suggesting
that a delay in myotube enlargement is observed in regener-
ating Bgn/0 muscle.
Interestingly, and also coincident with possible abnormal-
ities occurring after muscle precursor cell fusion, a second
difference in the regenerative process in biglycan-null mus-
cle was observed when the expression of a later differenti-
ation marker was studied: Bgn/0 muscle presented a
decreased embryonic myosin expression, even though the
total content of skeletal muscle myosin was similar in both
groups of mice (Fig. 6B). This decrease in embryonic
myosin content reflects a delayed and lesser peak of expres-
sion of the transcripts for the embryonic isoform of myosin(A) Western blots of chondroitinase-treated samples from DEAE-enriched
) mice. In Bgn+/0 muscle, an up-regulation of biglycan but not of decorin is
ycan, decorin up-regulation in regenerating muscle is observed on the same
rescence studies, an increase of decorin in the endomysium of regenerating
ction. As a control, biglycan immunodetection is shown in the last column.
ysium and regenerating myotubes basement membranes are indicated by an
by an arrow. The scale bar indicates 50 Am.
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quantitative RT-PCR (Fig. 6C).
Decorin is up-regulated in regenerating Bgn/0 skeletal
muscle
In mice with ablated individual SLRP genes, the possibil-
ity of a partial compensation by related SLRP members has
been described (Ameye and Young, 2002). We therefore
studied decorin core protein content in chondroitinase
ABC-treated DEAE-enriched extracts from control and
regenerating muscle. In Fig. 7A, Western blot studies on
samples from the seventh day after barium chloride injection
and from the 12th day, that is, towards the end of the
regeneration process (and when proteoglycan content is not
different from basal conditions), are presented. As expected,
in wild-type muscle, a transient increase of biglycan core
protein is observed and decorin core protein does not present
a significant variation. In contrast, an increase in decorin’s
core protein content was observed in biglycan-null muscle.
This increase in decorin expressionwas confirmed by indirect
immunofluorescence studies in cross sections from regener-
ating TA (Fig. 7B). Increased immunodetection of decorin
core protein was observed in Bgn/0 muscle from the fifth
and seventh day after barium chloride injection. Interestingly,
this augmented detection was localized in the interstitial
tissue but was more marked in the periphery of newly formed
myotubes, the usual biglycan localization (Fig. 3). These
results show that in biglycan-deficient skeletal muscle, there
is a transient increase in the amount of decorin during
regeneration.
Taken together, the results from the studies in biglycan-
null mice show that biglycan expression influences fiber
maturation and embryonic myosin expression during skeletal
muscle regeneration but is dispensable for the expression of
critical regulators as MyoD or myogenin and for the mor-
phological completion of the process. Moreover, skeletal
muscle regeneration in the absence of biglycan goes through
with an unexpected decorin up-regulation, which makes it
interesting to speculate a possible redundant function of
these SLRPs in skeletal muscle regeneration.Discussion
Decorin and biglycan are the only proteoglycan members
of the class I of SLRP family, as the third member of this
family, the related protein asporin, lacks the dipeptide
sequence required for glycosaminoglycan attachment (Henry
et al., 2001; Lorenzo et al., 2001). They contain 10 leucine-
rich repeats and present a high degree of homology, having
probably originated by gene duplication events during evo-
lution. They carry one and two CS or DS chains, respective-
ly, and the attachment of CS versus DS chains is variable and
tissue specific (Ameye and Young, 2002; Hocking et al.,
1998). Decorin, biglycan, and some other SLRPs are multi-functional proteins that bind to different types of collagen,
modulating collagen fibrillogenesis (reviewed in Iozzo,
1998). They also bind the three isoforms of TGF-h through
at least two sites, of high and low affinity, with Kd values of
1–20 and 20–200 nM, respectively (Hildebrand et al.,
1994). Some degree of controversy exists on the biological
activity of the proteoglycan/TGF-h complex, mostly based
in the case of decorin, which has been studied more exten-
sively. In models of fibrotic diseases, decorin application
improved the course of the disease (Border et al., 1992; Isaka
et al., 1996; Kolb et al., 2001), and no effect was observed
after biglycan administration (Kolb et al., 2001). Decorin
overexpression also inhibited TGF-h growth response in
CHO cells and arterial smooth muscle cells (Fischer et al.,
2001; Yamaguchi et al., 1990) but an opposite effect has
been observed in other systems (Riquelme et al., 2001;
Takeuchi et al., 1994). In the particular case of skeletal
muscle, inhibition of decorin expression by the stable trans-
fection of an antisense sequence encoding vector in C2C12
myoblasts produced an accelerated differentiation as conse-
quence of a reduced sensitivity to TGF-h signaling
(Riquelme et al., 2001). Similarly, a decreased growth
response to TGF-h was recently described in bone marrow
stromal cells from Bgn/0 mice (Chen et al., 2002). These
different observations may be explained in part as an effect
of localization, with the proteoglycan sequestering TGF-h
when bound to the ECM and favoring its interaction with its
transducing receptors when associated to the cell surface. In
general terms, decorin and biglycan have unique and diver-
gent distribution patterns, with decorin being preferentially
associated with collagen-rich connective tissues and bigly-
can localized at the cell surface of certain specialized cell
types. However, as shown in Fig. 3, in skeletal muscle,
decorin is also localized in the proximity of the cell surface,
as is evident from its immunostaining signal at the basement
membrane of myofibers in basal adult muscle and during
regeneration. Specific binding of biglycan and decorin to
separate cell surface molecules has been described. Biglycan
interacts through its CS chains with a-dystroglycan (Bowe et
al., 2000), and decorin interacts through its core protein with
the epidermal growth factor receptor (Santra et al., 2002).
Decorin can exert direct signaling effects on growth and
differentiation processes, up-regulating p21WAF1/CIP1 (De
Luca et al., 1996; Santra et al., 1997), and an effect for
biglycan on different signaling pathways is also suspected
(Kresse and Schonherr, 2001).
In this context, the observation of an increase in CS/DS
proteoglycan expression during skeletal muscle regenera-
tion that is mainly dependent on biglycan up-regulation,
normally of low expression in adult skeletal muscle, is of
particular interest (Figs. 1–3). Increased biglycan expres-
sion is also detected in growing skeletal muscle after birth
and in proliferating C2C12 myoblasts, being slowly down-
regulated with skeletal muscle differentiation (Fig. 4).
Considering the role that has been recently recognized for
proteoglycans in the control of cell growth and differenti-
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gestive of the possible participation of biglycan in the
myogenic process. Studies of skeletal muscle regeneration
in biglycan-null mice show differences in the expression of
differentiation markers and in the enlargement of regener-
ated myofibers during their maturation (Fig. 6) but do not
support a more definite role, as these mice maintain a
relatively normal capacity to form and regenerate skeletal
muscle at the beginning of adult life (Fig. 5). However,
these differences in the regenerative process and the con-
comitant transient up-regulation of the related proteoglycan
decorin (Fig. 7) suggest the participation of biglycan in the
regulation of skeletal muscle regeneration and the possible
appearance of alternate regulatory mechanisms for the
maintenance of the tissue response.
Skeletal muscle regeneration is a complex process that is
not yet completely understood. Following skeletal muscle
injury, several signals are released from degenerating myo-
fibers, infiltrating inflammatory cells and remodeling ECM
that can affect reparative myogenesis. Between days 3 and 5
after toxic muscle injury, a morphological shift from a
proliferative phase of muscle precursor cells to a phase of
muscle differentiation occurs (Yan et al., 2003). Biglycan up-
regulation is observed during the early phase of skeletal
muscle differentiation and is detected, accordingly, in the
periphery of newly formed myotubes. In vitro studies of the
C2C12 cell line show that its expression is high in myoblasts
and then decreases with differentiation. C2C12 myoblasts in
growth conditions proliferate and express MyoD and myf-5,
properties that make them resemble activated satellite cells.
Thus, the in vivo and in vitro data on biglycan expression in
skeletal muscle, taken together, suggest it is expressed at low
levels by mature myofibers, but after injury is probably up-
regulated, both in activated muscle precursor cells and
growing myotubes, to progressively decrease again with
maturation of the fibers. Considering the possible role of
biglycan as a modulator of TGF-h signaling, it is interesting
to note that this pattern of expression bears some similarities
to the described expression of TGF-h2 during muscle
regeneration, which was found increased in fusing satellite
cells and newly formed myotubes (McLennan and Koishi,
1997). Biglycan, or decorin in its absence, may have a role in
the fine-tuning of TGF-h2 signaling in nascent myotubes.
Biglycan expression, however, is not necessary for skel-
etal muscle regeneration, as is shown by the studies in Bgn/
0 mice. The concomitant up-regulation of decorin in regen-
erating biglycan-deficient muscle, however, precludes us
from a full appreciation of the respective roles of the SLRPs
in the regulation of this process. Despite the fact that decorin
and biglycan bear distinct functions, as is evident by the
different phenotypes of each knockout mice (Danielson et
al., 1997; Xu et al., 1998), an important degree of redun-
dancy has been revealed by the study of double-deficient
mice (Corsi et al., 2002). The phenotype of the double
knockout is severe: they cannot breed and the number of
double-deficient animals obtained for heterozygous breedersis much lower than the expected Mendelian frequencies.
When analyzed, these mice show a bone phenotype that is
much more severe than biglycan single-deficient mice and
skin fragility that is reminiscent of the decorin single
deficient phenotype. The difficulty in the breeding of these
double mutant mice makes it extremely arduous to obtain
sufficient number of animals to perform studies to follow the
regeneration process.
A possible redundancy in the functions of biglycan and
decorin during skeletal muscle regeneration, however, would
not be sufficient to maintain completely the features of the
process observed in wild-type mice. The observed delay in
regenerated fiber growth probably reflects differences in
events later than myogenin expression and cell fusion.
Interestingly, this delay in fiber enlargement resembles the
phenotype described for skeletal muscle regeneration in
tensin-null mice (Ishii and Lo, 2001), an intracellular sarco-
lemma protein that is recruited to focal adhesions, where it
binds to actin filaments and interacts with phosphotyrosine-
containing proteins, and that is also localized in some NMJs.
Biglycan, and not decorin, participates in the dystrophin-
associated protein complex, and Bgn/0 mice present a mild
myopathy with signs of membrane disruption and necrosis in
a subgroup of fibers (Bowe et al., 2000; Rafii et al., 2000). A
role for dystroglycan and the correct assembly of the
dystrophin-associated protein complex for successful skele-
tal muscle regeneration have been recently proposed (Cohn
et al., 2002). Although the temporal expression patterns of
biglycan and a-dystroglycan differ during muscle regenera-
tion (data not shown), both molecules are present during this
time, and thus it is possible that a mechanism involving their
interaction may come into play during regeneration.
Forming muscle masses express a succession of myosin
heavy chain isoforms during embryogenesis, from embry-
onic to adult, through neonatal and perinatal isoforms
(reviewed in Weiss and Leinwand, 1996). The functional
importance of these transitions and of the developmental
expression of myosin heavy chain isoforms is not well
understood, as neither are the complete mechanisms regu-
lating their expression. However, the observed differences in
the transient expression of embryonic myosin may reflect
some mechanism of control by ECM signals on the myo-
genic programs elicited during regeneration independently
of MRF expression.
In summary, class I SLRP expression during skeletal
muscle regeneration in mouse TA was studied. A dramatic,
transient up-regulation of biglycan was observed while
decorin, the most abundant proteoglycan in normal adult
skeletal muscle, only exhibits minor variations during the
process. These proteoglycans are regulated in opposite
directions during in vitro myogenesis, with decorin expres-
sion highest in myotubes and biglycan’s most prominent in
proliferating myoblasts. Studies of skeletal muscle regener-
ation in biglycan-deficient mice suggest that although bigly-
can expression is dispensable for the overall occurrence of
the regenerative process, its absence affects regenerated fiber
J.C. Casar et al. / Developmental Biology 268 (2004) 358–371370growth and the transient expression of nonadult myosin
isoforms. Moreover, transient decorin up-regulation in the
absence of biglycan appears as a possible compensatory
mechanism and allows us to speculate that SLRPs play a role
in skeletal muscle regeneration.Acknowledgments
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